CAUTION: This email originated from outside of the DC Government. Do not click on links or open attachments unless you recognize the sender and know that the content is safe. If you believe that this email is suspicious, please forward to <u>phishing@dc.gov</u> for additional analysis by OCTO Security Operations Center (SOC).

MaryBeth/Andre,

We have performed the requested analysis to determine some alternatives to bring the proposed Bronze Copay plan, with the change to covering the proposed cardiovascular services and drugs at \$0 member cost sharing, within the 65% de minimis range of the AV Calculator. A few options are summarized below:

- Current Plan
 - The starting plan was the 2024 Bronze Copay plan with \$0 member cost sharing for the proposed cardiovascular services and drugs, which includes all four add-on scenarios from Whitman Walker
 - Metal AV = 65.35%
- Option 1
 - Increases the maximum out-of-pocket from \$9,150 to \$9,400 (+\$250)
 - Metal AV = 64.93%
- Option 2
 - Increases the generic drug copay from \$25 to \$30 (+\$5)
 - Metal AV = 64.75%
- Option 3
 - o Increases the copay for the following service categories
 - PCP: \$45 to \$55 (+\$10)
 - Specialist: \$105 to \$125 (+\$20)
 - Office Visit Mental Health/Substance Abuse: \$45 to \$55 (+\$10)
 - Metal AV = 64.92%

The least disruption to members and to premiums is likely to come from Option 2 as it's only a \$5 increase to generic drugs. As we previously discussed, there are likely a fair amount of generic drugs with a lower cost than the current \$25 copay that would not be impacted by this proposed change (i.e., the member will pay the full cost regardless of a \$25 or \$30 copay for drugs which cost \$25 or less). If there are any questions or items you want to discuss further, please let us know.

Peter Scharl, FSA, MAAA He/Him/His

Senior Manager | Actuarial Consulting

Oliver Wyman | 411 East Wisconsin Avenue | Milwaukee, 53202 M +1 (920) 980-4213 | T +1 (414) 277-4620 Assistant: <u>Denise Barker</u> | +1 (414) 223-7983

OliverWyman

A business of Marsh McLennan

This e-mail and any attachments may be confidential or legally privileged. If you received this message in error or are not the intended recipient, you should destroy the e-mail message and any attachments or copies, and you are prohibited from retaining, distributing,

disclosing or using any information contained herein. Please inform us of the erroneous delivery by return e-mail. Thank you for your cooperation. For more information on how we use your personal data please see our **Privacy Notice**.